Diagnostic Contribution, Prognosis and Physiopathological Aspects in Arrhythmogenic Cardiomyopathy. (ACORE)

Assistance Publique - Hôpitaux de Paris

Status: Not yet enrolling

Conditions: Arrhythmogenic Cardiomyopathy

Treatments: Biological: Prospective; Other: Retrospective

Study type: Observational

Funder types: Other

Identifiers

NCT05569356

APHP210985

2022-A00283-40 (Other Identifier)

Details and patient eligibility

About

This study aims to identify novel inflammatory biomarkers in AC, whether in circulating blood, in situ or as imaging biomarkers to better understand the pathophysiology of the disease and then to determine contribution to the clinical management of patients.

Full description

The treatment of AC remains based on palliative measures aimed at treating the consequences of the disease: antiarrhythmic treatments, defibrillator, treatments for heart failure. The identification of new biomarkers, in particular circulating ones, would make it possible to open pathophysiology avenues which, in the long term, could lead to therapies targeted to autoimmunity or inflammation.

Many scientific and medical questions remain unanswered and require precise databases on the diagnostic and prognostic evaluation of this pathology.

The objective of this study is to identify novel inflammatory biomarkers in patients with AC by studying the autoimmunity, inflammatory, and immunological profiles through blood samples and myocardial biopsies.

Enrollment: 300 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adult patient (age ≥ 18 years old)
2. Patient with a probable or confirmed diagnosis of cardiomyopathy according to the diagnostic criteria of the international task force
3. Patient carrying a pathogenic mutation responsible for cardiomyopathy
4. Patient informed individually of the research

Exclusion criteria

1. Patients under curatorship/guardianship
2. Pregnant women
3. Patients who expressed their opposition to participate in the study

Trial design

300 participants in 2 patient groups

Arrhythmogenic Right Ventricular Cardiomyopathy (Prospective)

Treatment:

Biological: Prospective

Arrhythmogenic Right Ventricular Cardiomyopathy (Retrospective)

Treatment:

Other: Retrospective